FilingSEC EDGAR8-K
Lipocine Initiates Phase 3 BLOOM Study for LPCN 1154 in Postpartum Depression
· SEC accepted
StagePhase 3
Filing content
Lipocine has initiated the Phase 3 BLOOM study for LPCN 1154 to treat postpartum depression, with the first participant dosing expected in early Q4 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…